We want to take up the challenge posed by Nadar and cols. in their May editorial about managing hypertension during the COVID-19 pandemic [1]. Their concern that patients with chronic illnesses would be forgotten in the fight against the paradigm of a transmissible virus and result in collateral damage reached the public domain since June [2]. In mid October the number of new confirmed cases is still increasing in the Americas, South-East Asia and Europe according to the World Health Organization [3]; lockdowns have been reinstalled in various zones and widely available vaccines are far from around the corner. In the present situation it is urgent to mitigate the collision of non-transmissible conditions with the rapid spread of the novel COVID infection by new patterns of interaction between all the protagonists involved in health care.

An unexpected and beneficial collateral effect of the prolonged worldwide sanitary crisis is the shift in the balance between critical and stable health conditions by addressing most of the control of hypertension and other chronic conditions to the virtual attention. The American Society of Preventive Cardiology has proposed virtual team care in order to override the pandemic [4]. This relatively new mode has been well accepted by patients and validated by randomized clinical trials, metanalysis and systematic reviews that show similar blood pressure control than the conventional form, but if accompanied by education and counselling obtains extra benefits [5,6,7,8]. In addition, telemedicine offers several advantages (Table 1), including more equal and patient-centered health care in times in which vulnerable groups increase, receive the greatest economic and sanitary toll and require individual support. The way to virtual attention has been paved by affordable and validated automatic blood pressure monitors that permit adequate home controls when performed under the recommendations of the American Heart and the American Medical Associations [9]. Lastly, by the massive incorporation of virtual connections to daily life derived by the restrictions imposed by COVID-19.

Table 1 Advantages of telemedicine in the care of hypertensives in times of COVID-19.
Full size table

Free access to ongoing validated protocols would help to rapidly integrate this relatively new form of care, but in the meantime we propose a simple and inexpensive framework that might be adapted to local practices with a pen, paper and digital connections (Fig. 1). This strategy is possible by incorporating graduates in training in the health careers to build data bases to contact patients while the risks of acquiring COVID-19 persist. Reaching out for patients potentiates the attachment between the health team and subjects under their care, which will improve adhesion to controls, therapy and recommendations. In this occasion it is necessary to identify whether the patient has a self-measurement device. In case he has none, pharmacies can play a role. In low income areas medical societies, pharmaceutical industries and profit and non-profit organizations among others must unite efforts to provide individual monitors.

Fig. 1
figure 1

Actions included in the first two controls with hypertensive patients (left and right pannel) separated by the review of the clinical file by the health team in the interim period (hatched circle).

Full size image

Once the crisis is over, the continuity in the use of telehealth in hypertension will require returning to previous protocols, guidelines and quality standards that guarantee safety, ethics, reliability and legal issues. But while health systems continue to be overloaded for an unpredictable time this—or other simple proposals—could contribute to return to a continuous combination of face-to-face and virtual attention that previously diagnosed hypertensives need.